Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.74 USD
-0.01 (-1.79%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $0.74 0.00 (0.38%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CUE 0.74 -0.01(-1.79%)
Will CUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CUE
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
CUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
Other News for CUE
12 Health Care Stocks Moving In Wednesday's Intraday Session
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing ...
CUE-101 Shows Promising Phase 2 Results for Cue Biopharma (CUE) | CUE Stock News
Cue Biopharma provides clinical update on CUE-101, saw ORR of 50%
12 Health Care Stocks Moving In Wednesday's After-Market Session